ストックスクリーナーアプリを入手
91.51
1.88%
1.69
プレマーケット:
90.97
-0.54
-0.59%
前日終値:
$89.82
開ける：
$91.18
24時間の取引高:
6.10M
Relative Volume:
1.17
時価総額：
$283.73B
収益：
$58.07B
当期純損益:
$9.40B
株価収益率:
30.39
EPS:
3.0113
ネットキャッシュフロー:
$9.87B
1週間 パフォーマンス:
+0.73%
1か月 パフォーマンス:
+4.61%
6か月 パフォーマンス:
+23.95%
1年 パフォーマンス:
+36.22%
1日の値動き範囲:
$89.70
$91.66
1週間の範囲:
$89.67
$91.66
52週間の値動き範囲:
$61.24
$94.02
Astrazeneca PLC Stock (AZN) Company Profile
名前
Astrazeneca PLC
セクター
電話
44 20 3749 5000
住所
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
AZN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
91.51 | 278.49B | 58.07B | 9.40B | 9.87B | 3.0113 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-27 | 再開されました | Jefferies | Buy |
| 2025-10-16 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-02-13 | アップグレード | UBS | Neutral → Buy |
| 2025-02-12 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-20 | アップグレード | UBS | Sell → Neutral |
| 2024-11-06 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-09-13 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-16 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-02-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Sell |
| 2024-01-03 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-09-25 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-07-12 | アップグレード | UBS | Neutral → Buy |
| 2023-07-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-04-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2022-09-15 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | アップグレード | Argus | Hold → Buy |
| 2022-06-14 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-11 | アップグレード | DZ Bank | Sell → Hold |
| 2021-12-07 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-12 | 再開されました | JP Morgan | Overweight |
| 2021-04-12 | ダウングレード | Argus | Buy → Hold |
| 2021-03-16 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | アップグレード | UBS | Neutral → Buy |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-12-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | アップグレード | UBS | Sell → Neutral |
| 2020-11-11 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2019-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-10-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-02 | ダウングレード | UBS | Neutral → Sell |
| 2019-02-05 | 開始されました | Exane BNP Paribas | Outperform |
| 2019-01-25 | アップグレード | Shore Capital | Hold → Buy |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-08-16 | ダウングレード | Jefferies | Buy → Hold |
| 2018-03-19 | アップグレード | Jefferies | Hold → Buy |
| 2018-02-06 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-05 | 繰り返されました | Bernstein | Outperform |
| 2018-01-18 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-12-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | アップグレード | Bernstein | Mkt Perform → Outperform |
すべてを表示
Astrazeneca PLC (AZN) 最新ニュース
Why is AstraZeneca PLC (AZN) One of the Best Pharma Stocks to Invest In? - Insider Monkey
AstraZeneca: A Rare Compound Growth Opportunity In Biopharma (AZN) - Seeking Alpha
Aug Ideas: Will Precidian ETFs Trust AstraZeneca PLC stock maintain strong growthJuly 2025 Sector Moves & Smart Allocation Stock Reports - BỘ NỘI VỤ
Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks - Benzinga
AstraZeneca price target raised to $105 from $95 at TD Cowen on growth outlook - Investing.com UK
AstraZeneca (AZN) Begins Phase 3 Trial of Enhertu for Ovarian Ca - GuruFocus
Quantbot Technologies LP Reduces Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Sold by Hsbc Holdings PLC - MarketBeat
Cerity Partners LLC Increases Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca (LSE:AZN): Assessing Valuation After a Strong Year-to-Date Share Price Rally - Yahoo Finance
AstraZeneca PLC (NASDAQ:AZN) Nasdaq Futures Science-Driven Growth - Kalkine Media
AstraZeneca PLC ADR Rises Monday, Outperforms Market - 富途牛牛
Pillar Biosciences and AstraZeneca expand liquid biopsy access partnership to China - marketscreener.com
Pillar Biosciences and AstraZeneca Expand Liquid Biopsy Access Partnership to China - marketscreener.com
AstraZeneca is top pharma tip for 2026, with GSK left trailing - Proactive Investors
How Are AstraZeneca’s Scientific Initiatives Influencing Its FTSE 100 Standing? - Kalkine Media
AstraZeneca (AZN) Price Target Raised by JPMorgan - GuruFocus
First Trust Advisors LP Acquires 217,595 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Bought by Invesco Ltd. - MarketBeat
1832 Asset Management L.P. Acquires 18,543 Shares of AstraZeneca PLC $AZN - MarketBeat
Surprises Report: Is AstraZeneca PLC ZEG stock resilient in recession scenariosLong Setup & High Accuracy Investment Signals - BỘ NỘI VỤ
AstraZeneca PLC $AZN Shares Sold by Capital Fund Management S.A. - MarketBeat
AstraZeneca: An Insight Into The Growth Potential Of Imfinzi - Smartkarma
SCS Capital Management LLC Purchases 142,331 Shares of AstraZeneca PLC $AZN - MarketBeat
Marshall Wace LLP Buys 623,902 Shares of AstraZeneca PLC $AZN - MarketBeat
Guggenheim Capital LLC Has $13.58 Million Stock Position in AstraZeneca PLC $AZN - MarketBeat
UK stocks gain ahead of key US inflation data; AstraZeneca rises - marketscreener.com
Is AstraZeneca PLC (Common Stock) (ZEGA) stock a buy on weaknessWeekly Profit Summary & Fast Gain Stock Tips - Newser
Epoch Investment Partners Inc. Trims Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca selects Salesforce’s Agentforce for global HCP engagement By Investing.com - Investing.com Nigeria
Is Precidian ETFs Trust AstraZeneca PLC stock a top dividend aristocrat candidateTrade Risk Assessment & Expert Approved Momentum Trade Ideas - Newser
Why Precidian ETFs Trust AstraZeneca PLC stock benefits from AI revolutionQuarterly Investment Review & AI Enhanced Execution Alerts - Newser
Has AstraZeneca’s Strong 30% Rally Left Further Upside in 2025? - Yahoo Finance
Salesforce’s Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement - Yahoo Finance
AstraZeneca Stake Adjustment by Capital Group - TipRanks
AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report - Sahm
ASTRAZENECA : Bernstein remains its Buy rating - marketscreener.com
FDA Streamlines Clinical Study Requirements, Impacting AstraZene - GuruFocus
AstraZeneca (AZN) Could Benefit from FDA's Shift to Single Study Approval - GuruFocus
REGAstraZeneca PLCHolding(s) in Company - TradingView
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH - marketscreener.com
Neurimmune expands collaboration with AstraZeneca to develop and commercialize Fibril Depleter NI009 for AL Amyloidosis - marketscreener.com
AstraZeneca news live: price tests Ichimoku Kijun support — bullish momentum meets consolidation risks - Traders Union
M&T Bank Corp Has $15.30 Million Stock Position in AstraZeneca PLC $AZN - MarketBeat
Bernstein Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Raises Target Price to $245.46 - 富途牛牛
AstraZeneca PLC Advances Hematology and Cell Therapy Ambition with Largest-Ever Presence at ASH - marketscreener.com
AstraZeneca (AZN) Set to Showcase Hematology Innovations at ASH 2025 - GuruFocus
New York State Common Retirement Fund Has $13.74 Million Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca to showcase hematology advances at ASH annual meeting By Investing.com - Investing.com UK
Arrowstreet Capital Limited Partnership Cuts Position in AstraZeneca PLC $AZN - MarketBeat
Guggenheim Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Raises Target Price to $206.76 - 富途牛牛
Astrazeneca PLC (AZN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):